SCRI CCCIT Ges.m.b.H.

The SCRI CCCIT Ges.m.b.H. site in Salzburg is highly active in hematologic malignancies, with research focused on diseases such as multiple myeloma, acute myeloid leukemia, lymphoma, chronic lymphocytic leukemia, and myelodysplastic syndromes. These trials are generally designed to test new treatment options, improve disease control, and deepen understanding of how patients respond to therapy.

• Studies in multiple myeloma and relapsed or refractory myeloma are evaluating better ways to improve response and prolong remission.
• Research in lymphoma includes diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and Waldenström’s macroglobulinemia.
• Trials in acute myeloid leukemia and myelodysplastic syndromes are aimed at improving outcomes for newly diagnosed and higher-risk patients.

Overall, this therapeutic area reflects a strong emphasis on blood cancer research, with the goal of advancing more effective and durable treatments.

Another major focus at this hospital-based research center is solid tumor oncology, especially breast cancer. The studies cover early, locally advanced, and metastatic disease, and are intended to assess new therapies, refine treatment strategies, and reduce the risk of recurrence.

• Breast cancer research includes HER2-positive, HER2-negative, ER-positive, and triple-negative disease.
• Several trials explore approaches for early breast cancer, locoregional recurrence, and metastatic breast cancer.
• The site also studies colorectal cancer, gastric cancer, pancreatic cancer, and cholangiocarcinoma.

These projects aim to improve treatment effectiveness across a broad range of oncology settings, from surgery-adjacent care to advanced disease.

The site also contributes to research in thoracic and head and neck cancers, alongside other advanced solid tumors. The main purpose of these trials is to evaluate whether newer treatment combinations can improve survival, disease control, and symptom management in hard-to-treat cancers.

• Non-small cell lung cancer and small cell lung cancer are key areas of investigation.
• Head and neck squamous cell carcinoma studies include both resectable and unresectable disease.
• Additional work includes advanced melanoma, urothelial carcinoma, and other solid tumors.

At SCRI CCCIT Ges.m.b.H., this research helps expand options for patients with cancers that often require more personalized and effective treatment approaches.

In addition to cancer studies, the site supports research in immune system diseases and cell physiological phenomena, with a strong interest in cell-based therapies and immune-directed treatment. These trials are designed to test innovative approaches, monitor safety over time, and better understand how advanced therapies work in patients.

• Trials involving CAR T-cell therapy and gene-modified T cells are a prominent part of the research portfolio.
• Studies also examine lymphoid cancers through immune-targeted strategies such as bispecific antibodies.
• Some projects address autoimmune disease, including Sjögren’s disease.

This area highlights the site’s role in advancing next-generation immunotherapy and in improving long-term understanding of treatment benefit and safety.

The research portfolio at this Austrian clinical trial site also includes important work in digestive system diseases, especially gastrointestinal cancers and related conditions. These studies are focused on testing new therapies, improving disease control, and identifying better treatment options for patients with advanced or recurrent disease.

• Colorectal cancer, including metastatic and unresectable forms, is a major area of study.
• Trials in gastric cancer, gastroesophageal junction cancer, and esophagogastric adenocarcinoma are evaluating new treatment strategies.
• Research also covers pancreatic ductal adenocarcinoma and biliary tract cancer, including cholangiocarcinoma.

These studies reflect a clear effort to improve outcomes in gastrointestinal oncology, where treatment needs remain substantial.

Beyond its major oncology programs, the site has additional studies in prostate cancer, melanoma, and selected immune-mediated or inflammatory conditions. The purpose of this research is to broaden treatment choices, assess effectiveness in specific patient groups, and support more tailored care.

• Metastatic castration-resistant prostate cancer is among the non-hematologic cancers under investigation.
• Melanoma studies focus on patients with previously treated advanced disease.
• Some trials explore broader biologic questions related to cell behavior and treatment response.

With 99 clinical trials and 12 investigators, the SCRI CCCIT Ges.m.b.H. program in Salzburg shows a wide-ranging commitment to advancing care across multiple therapeutic areas.